| FDA Clears Affymax and Takeda's Once-Monthly ESA for Anemic CKD Patients on ... - Genetic Engineering News |
|
|
Genetic Engineering News Affymax and partner Takeda Pharmaceutical confirmed FDA approval of Omontys® (peginesatide) injection for the treatment of anemia in adult chronic kidney disease (CKD) patients on dialysis. The firms say the drug is the only once-monthly ... Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS |